Clinical trials: Vascular And Immunologic Diseases
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Bryostatin and Vincristine in B-Cell Malignancies
This phase I trial is studying the side effects and best dose of bryostatin-1 when given together with vincristine in treating patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or multiple myeloma.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00003166
- Testing
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia.
- Trial name
- NCT00667329
- Testing
- 2CdA, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to test a new drug called carfilzomib. It is a type of drug called a proteasome inhibitor. Proteasome breaks down proteins that are no longer useful to the cell.
- Trial name
- NCT01351623
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Spontaneous Urticaria (CSU)
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines.
- Trial name
- NCT07665996
- Testing
- TLL-018
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Metal Allergy, Contact Allergy
Metal Allergy In-Stent Restenosis Study
In-stent restenosis remains one of the most challenging problems in patients after coronary artery angioplasty. Angiographically, it is discovered in 10% of the patients after drug-eluting stent (DES) implantation.
- Conditions
- Metal Allergy, Contact Allergy, Restenoses, Coronary, In-stent Restenosis
- Trial name
- RESTALL (NCT03588962)
- Testing
- In-stent restenosis
- Volunteers
- 1,000 people
- Sponsor
- Silesian Centre for Heart Diseases
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Rheumatoid Arthritis, Giant Cell Arteritis
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
A single dose, two period trial where participants will be given either of 3 Tocilizumab product on Day 1 during period 1 and either one of the remaining 2 Tocilizumab products on Day 1 period 2.
- Trial name
- NCT04885829
- Testing
- Tocilizumab Prefilled Syringe
- Where
- 4 sites in Australia, India and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
This exploratory, single-arm, open-label study will evaluate the safety and preliminary efficacy of YTS109 cell therapy in pediatric patients with relapsed/refractory autoimmune diseases, including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT07439029
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Fudan University
Hereditary Angioedema Type I, Angioneurotic Edema
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
A multicentre study to investigate pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be…
- Trial name
- NCT00119431
- Testing
- C1 inhibitor concentrate
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Prothya Biosolutions
Multiple Myeloma
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NCT01568294
- Testing
- pomalidomide
- Where
- 8 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Celgene
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of…
- Trial name
- EMBRACE (NCT06421675)
- Testing
- Elranatamab injection
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant.
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT00114101
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 140 sites in United States
- Volunteers
- 460 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Hematological Neoplasms
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.
- Trial name
- NCT00440765
- Testing
- bortezomib
- Where
- 44 sites in Netherlands
- Volunteers
- 331 people
- Sponsor
- Janssen-Cilag B.V.
Bone Marrow / Autologous Transplants
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
- Trial name
- NCT01738373
- Testing
- Plerixafor
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Genzyme, a Sanofi Company
Infection, Heart Failure
Prediction of Expected Length of Hospital Stay Using Machine Learning
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT04784351
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Chronic Spontaneous Urticaria (CSU), Allergic Asthma
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the…
- Trial name
- ROLL'YN-OMA (NCT07425639)
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
Multiple Myeloma and Plasma Cell Neoplasm
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00499577
- Testing
- CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of Maryland Greenebaum Cancer Center
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple…
- Trial name
- NCT06655519
- Testing
- CAR-T（RD140 injection）
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.